Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking

SARS-CoV-2 therapeutic antibody discovery efforts have met with notable success but have been associated with a generally inefficient process, requiring the production and characterization of exceptionally large numbers of candidates for the identification of a small set of leads. Here, we show that...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:bioRxiv
Egile Nagusiak: Shiakolas, Andrea R., Johnson, Nicole, Kramer, Kevin J., Suryadevara, Naveenchandra, Wrapp, Daniel, Periasamy, Sivakumar, Pilewski, Kelsey A., Raju, Nagarajan, Nargi, Rachel, Sutton, Rachel E., Walker, Lauren, Setliff, Ian, Crowe, James E., Bukreyev, Alexander, Carnahan, Robert H., McLellan, Jason S., Georgiev, Ivelin S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cold Spring Harbor Laboratory 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183015/
https://ncbi.nlm.nih.gov/pubmed/34100018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.06.02.446813
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak